Neuren is significant undervalued ..
Neuren Pharma ( NEU.AX)
Marketcap: only 48 million A$
Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG Phase 3 ongoing
NNZ-2566 Severe TBI Phase 2a (deal with US Army)
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Apathy Phase 2b
Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva™ in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate® in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.
- Forums
- ASX - By Stock
- cheapest biotech stock on the asx
Neuren is significant undervalued ..Neuren Pharma (...
Featured News
Add SRX (ASX) to my watchlist
|
|||||
Last
13.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $56.24M |
Open | High | Low | Value | Volume |
13.0¢ | 13.5¢ | 13.0¢ | $109.3K | 836.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 365703 | 13.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
13.5¢ | 812922 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 365703 | 0.130 |
6 | 379702 | 0.125 |
2 | 288500 | 0.120 |
1 | 135000 | 0.115 |
3 | 23177 | 0.097 |
Price($) | Vol. | No. |
---|---|---|
0.135 | 308222 | 2 |
0.140 | 773121 | 13 |
0.145 | 280000 | 3 |
0.150 | 109631 | 6 |
0.160 | 70000 | 1 |
Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online